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Abstract:
Introduction: Topiramate is an effective, popular prophylactic migraine treatment that is 
approved for use in adults and adolescents. Due to its multiple mechanisms of action, topiramate 
has multiple potential safety issues, including systemic and central nervous system adverse 
events, that may complicate therapy. These include weight loss, metabolic acidosis, renal calculi,
acute angle closure glaucoma, visual distortions, and cognitive slowing. This review highlights 
both common and unusual safety issues associated with topiramate use, including use in 
pregnancy or lactation and important drug interactions. 
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Introduction:
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Topiramate is approved by the Food and Drug Administration (FDA) for the prevention of 
migraine in adults [1,2]and adolescents [3,4]. The usual dose of topiramate for migraine is 100 
mg, because this dose has the best balance of efficacy and low adverse events (AEs) [5]. The 
doses used in clinical practice, however, may vary considerably for individual patients and 
disorders and may be higher for some off-label uses, such as chronic migraine or idiopathic 
intracranial hypertension [6]. 
Although topiramate was originally investigated for its potential to treat gluconeogenesis, it was 
subsequently found to be effective in animal models of epilepsy, and found to be effective in 
humans.  [7] Topiramate is FDA-approved for the adjunctive treatment of partial-onset seizures, 
primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome in adults and children 2
years old or greater [8,9]. Recently the FDA approved a combination of phentermine and 
topiramate for the treatment of obesity in association with hypertension, type 2 diabetes, or 
dyslipidemia [10]. Off-label uses of topiramate in headache disorders include chronic migraine 
[11], trigeminal neuralgia [12], cluster headache [13], and idiopathic intracranial hypertension 
[14].
Mechanism of Action
Topiramate has numerous pharmacologic actions including (1) increasing gamma-aminobutyric 
acid (GABA) activity at GABA-A receptors; (2) inhibiting carbonic anhydrase isoenzmes II and 
IV; (3) blocking voltage-dependent sodium and calcium channels; (4) antagonism of the of 
AMPA/kainate subtype of the glutamate receptor; and (5) antagonism of 5-HT2C receptors 
[15].Compared to acetazolamide, tolerance to the anticonvulsant effects of topiramate is 
significantly longer. (Anderson RE, Chiu P, Woodbury DM, Epilepsia 1989)The exact 
mechanism of action that allows topiramate to be effective in migraine prophylaxis is unclear but
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may relate to inhibition of cortical spreading depression [16]. These actions contribute to 
multiple potential AEs with topiramate use, including both systemic and central nervous system 
(CNS) events. In some cases, such as antagonism of 5-HT2C receptors causing anorexia or 
carbonic anhydrase inhibition triggering metabolic acidosis and paresthesias, the cause of these 
AEs is fairly well understood. The cause of CNS AEs is less clear. In many cases the AEs are 
related to the dose used. 
Topiramate is renally excreted, has peak levels at 2 hours and a half-life of 21 hours. Blood 
plasma concentration increases linearly as a function of dose.  [17] Topiramate binds poorly to 
plasma proteins (about 15%), meaning the drug should be dosed after dialysis in patients with 
renal failure.
This review will focus on common, serious, and unusual AEs associated with topiramate use, 
utilizing data from large clinical trials, case series, and case reports. Systemic and CNS AEs will 
be considered separately, as will the use of topiramate in pregnancy and lactation and drug 
interactions. 
Safety Evaluation in clinical studies and postmarketing data
Systemic AEs
Weight loss and anorexia
Anorexia and weight loss were common AEs in topiramate clinical trials. In some cases, weight 
loss is desirable, and obesity is among the indications for topiramate. In the original 26-week 
trials, anorexia rates were 11%, 13% and 14%, respectively, in patients taking the 50, 100 and 
200 mg doses, respectively [18,19], while weight loss occurred in 5%, 10% and 12% of patients. 
Those with a higher baseline weight were more likely to lose weight. Many patients reported 
disturbance in food taste, such as causing carbonated beverages to taste “ﬂat” (19% on 50 mg, 
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10% on 100 mg, and 14% on 200 mg compared with 2% on placebo). This is also seen with 
other anticonvulsant drugs (i.e., acetozolamide and zonisamide). 
Nausea and other gastrointestinal AEs
In clinical trials for migraine, nausea was more common in those using topiramate than in those 
on placebo (9% 50 mg, 13% 100 mg, and 14% 200 mg vs. 8% placebo). Timing of drug use may 
affect rates of nausea: although food does not affect topiramate’s effectiveness, taking it with a 
meal may reduce nausea [18,19]. Diarrhea is another common AE, with 9%, 11% and 11% of 
those in the 50 mg, 100 mg and 200 mg groups, respectively, suffering from this condition, 
compared to 4% with placebo.
Paresthesias, metabolic acidosis and hypokalemia
Paresthesias are an extremely common AE in those taking topiramate. In migraine trials, 
topiramate users were much more likely to experience them, even at low doses (35% 50 mg, 
51% 100 mg, 49% 200 mg compared to 6% placebo). The cause of these paresthesias may be 
related to underlying metabolic acidosis. In clinical trials, lowering of bicarbonate levels 
occurred in 44% of those taking 200 mg/day, 39% taking 100 mg/day, 23% taking 50 mg/day, 
and 7% taking placebo. The incidence of abnormally low serum bicarbonate (either below 17 
mEq/L or a decrease greater than 5 mEq/L) was 11% at 200 mg, 9% at 100 mg and 2% at 50 mg,
compared with <1% of placebo. This may cause hyperventilation, fatigue, or anorexia and in rare
cases, renal failure, cardiac arrhythmias, or stupor [20]. Chronic metabolic acidosis may also 
decrease growth rate in children. Treatment duration does not appear to affect the prevalence of 
metabolic acidosis, but polymorphisms in the carbonic anhydrase type XII gene may influence 
the risk of its development [21]. Hypokalemia is also common, with about 7% to 10% of patients
taking topiramate having low serum potassium levels [22]. In another pediatric study, potassium 
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levels were significantly lower in those using topiramate (3.7 versus 4.0 mmol/L; P<0.03) [23]. 
Supplemental potassium may alleviate paresthesias in patients using topiramate [24]. The 
package insert by Janssen Pharmaceuticals, Inc. 2009 recommends monitoring serum 
bicarbonate at baseline and periodically after that, although no timeframe for repeat testing is 
specified [25]. Patients with severe respiratory disorders or those on a ketogenic diet may be 
particularly susceptible; bicarbonate supplements may be useful in symptomatic patients [26].
Renal calculi
The incidence of renal calculi in migraine clinical trials was 1% at 100 mg and 2% at 200 mg, 
compared with 0% for 50 mg and placebo. The increased rate of kidney stone formation is 
related to the fact that topiramate causes metabolic acidosis, hypokalaemia, hyperuricemia, and 
hypocitraturia (a promoter of renal stone formation) [22]. Topiramate causes increased urinary 
pH, bicarbonate excretion, fractional excretion of bicarbonate, and decreased urinary citrate. 
Those using topiramate are particularly more likely to develop calcium phosphate stones. Since 
the development of renal calculi takes months or years, this may be a delayed AE in topiramate 
users. Hydration, dietary changes, and a lower dose of topiramate may reduce this risk. 
Glaucoma, including angle closure glaucoma
Topiramate may rarely cause acute angle closure glaucoma as an idiosyncratic reaction. Signs 
and symptoms include uveal effusion, lens forward displacement, conjunctival injection, corneal 
edema, and increased intraocular pressure leading to vision loss. The risk of this serious reaction 
is highest in the first month after therapy is initiated, [27] and can cause sudden vision loss that 
requires urgent opthalmologic attention. Topiramate-induced glaucoma may be unilateral or 
bilateral, [28] and intraocular pressure may range from mildly to very highly elevated [29]. 
Treatment includes not covering the eye (which causes pupillary dilation), supine positioning, 
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medications, and, in refractory cases, surgical procedures, such as laser peripheral iridotomy.  
These patients should not continue on Topiramate. 
Rash and Stevens-Johnson syndrome
An erythematous rash occurred in 2% of pediatric patients in clinical trials (compared with 0% 
placebo) but was not reported in adult migraine trials. More severe reactions, such as erythema 
multiforme or Stevens-Johnson syndrome, are rare, but they are more common in patients taking 
multiple anti-convulsants  [30].
CNS AEs 
Cognitive Impairment and Fatigue
Topiramate may cause multiple cognitive AEs, which may limit therapy. In a study of topiramate 
for the treatment of epilepsy, treated patients had deficits of fluency, attention/concentration, 
processing speed, language skills, and working memory [31]. Persons with a history of 
psychiatric disorder are more likely to experience cognitive difficulties [32]. Verbal fluency is 
also impaired in persons with migraine and aura may be a risk factor for greater effects [33]. In 
clinical trials for migraine, memory difficulties (7% 50 mg, 7% 100 mg and 11% 200 mg 
compared with 2% placebo), attention difficulties (3% 50 mg, 6% 100 mg and 10% 200 mg 
compared with 2% placebo), language problems (7% 50 mg, 6% 100 mg and 7% 200 mg 
compared with 2% placebo) and psychomotor slowing (3% 50 mg, 2% 100 mg and 4% 200 mg 
compared with 1% placebo) were all greater in those using topiramate. Topiramate also is noted 
to increase incidence of fatigue (14% 50 mg, 15% 100 mg and 19% 200 mg compared with 11% 
placebo) and somnolence (8% 50 mg, 7% 100 mg and 10% 200 mg compared with 5% placebo).
 [18,19]
Pallinopsia
6
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Topiramate may cause visual disturbances such as pallinopsia, meaning an afterimage that 
persists after the visual stimulus has left. [34-36]. The effects were describing after drug approval
in a series of case reports. Patients may describe visual "trails" or afterimages to describe this. 
The cause of pallinopsia in this case is likely related to cortical dysfunction rather than retinal 
pathology [37]. Topiramate may also cause other visual perceptual abnormalities, such as "Alice-
in-Wonderland" syndrome [34]. Visual disturbances related to topiramate appear dose-related 
[34]and may occur with similar medications, such as zonisamide [36]. Reducing the dose is 
usually necessary for symptoms to resolve.
Topiramate in Pregnancy and Lactation
The FDA recently categorized topiramate as pregnancy category D (positive evidence of human 
fetal risk) based on studies that demonstrate a two-fold increased risk of cleft lip, and less 
commonly cleft palate, in mothers using topiramate during pregnancy [38,39]. Breast feeding 
infants have plasma levels that are about 10% to 20% of maternal levels. No particular AEs have 
been noted in the infants of breastfeeding mothers using topiramate [40], but experience has been
limited. 
Drug Interactions
Many anticonvulsants have significant interactions with topiramate. Phenytoin, carbemazepine, 
valproic acid, and lamotrigine may all increase topiramate clearance and decrease levels [41]. 
Concomitant valproic acid use may increase the risk of hyperammonemia and encephalopathy, 
especially in those with mitochondrial disease [42]. Hydrochlorothiazide may increase drug 
levels. Topiramate should be used with caution in those taking other carbonic anhydrase 
inhibitors, such as zonisamide or acetazolamide, as well as metformin, which is contraindicated 
in those with metabolic acidosis. Topiramate may increase levels of amitriptyline and decrease 
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levels of lithium, digoxin, and valproic acid. Higher doses of topiramate (over 200 mg/day) may 
decrease plasma concentrations of estrogens and progestins in patients taking oral contraceptives,
leading to lower efficacy rates. Topiramate can interact with CNS depressants, such as alcohol, 
especially in terms of cognition.
Comparison of safety with other drugs
Topiramate is one of four oral medications approved for treatment of migraine. The other 
medications are propranolol, timolol and divalproex sodium. Propanolol and timolol are both 
non-selective beta-blockers used for hypertension in addition to migraine, with fairly similar AE 
profiles. Divalproex sodium is approved for multiple forms of epilepsy and acute mania in 
bipolar disorder. Methysergide is also approved for migraine but is not currently available in the 
United States. A supraorbital transcranial stimulator (Cefaly) was recently approved for treatment
of migraine  [43] as well. In addition Onabotulinumtoxin A, given in a series of injections, is 
approved for the treatment of chronic migraine. Table 1 provides a comparison of significant AEs
for these medications  [44] . 
Table 1: FDA-approved medications for migraine and AEs
Drug(s) Common AEs Serious AEs
Propanolol, Timolol Bradycardia, hypotension, 
weight gain, dizziness, sexual 
dysfunction, vertigo, fatigue, 
exacerbation of peripheral 
vascular symptoms
Bronchospasm, depression of 
cardiac contractility, blunting 
of hypoglycemia symptoms.
Divalproex sodium Sedation, tremor, dizziness, 
weight gain, diplopia, 
thrombocytopenia.
Hepatotoxicity, pancreatitis, 
polycystic ovarian syndrome, 
neural tube defects
Onabotulinumtoxin A Injection site pain, neck Dysphagia, diplopia
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weakness, ptosis, cosmetic 
effects
Topiramate Weight loss, nausea, 
paresthesias, renal calculi
Metabolic acidosis, 
hypokalemia, cognitive 
effects
Conclusions
Topiramate is well-established as an effective treatment for migraine, and may be a first-line 
migraine prophylactic agent due to its lack of weight gain, effectiveness at lower doses than 
those used in epilepsy, and potential cost savings. When prescribing topiramate, clinicians need 
to be familiar with its AEs and titrate the drug appropriately. Topiramate may take weeks or 
months to become effective, and the recommended titration is 25 mg per week to an initial 
starting dose of 100 mg [2]. This is in contrast to its use in epilepsy which suggests a 50 
mg/week titration up to a minimum of 200 mg/day [45]. In patients experiencing AEs, a slower 
titration may be useful to reduce discontinuation. For less serious AEs, such as nausea or 
paresthesias, reassurance is important, as these tend to resolve with time and the need to lower 
the dose may be temporary. The frequency and importance of monitoring serum bicarbonate and 
potassium is unclear, especially in those on a stable dose with no clear AEs. In general, clinicians
should be aware of symptoms that suggest symptomatic metabolic acidosis and screen for it in 
those with symptoms or in those with systemic illness in general. For more problematic AEs, 
such as cognitive impairment, lowering the dose of topiramate or discontinuing it altogether 
should be considered. With skillful titration, patients may not perceive mental slowing or mood 
AEs, so clinicians should screen for these symptoms in patients taking higher doses. Patients 
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using topiramate for extended periods of time may develop drug tolerance leading to fewer AEs, 
or tachyphylaxis, which may require a higher dose or render the drug ineffective. 
Expert Opinion:
Topiramate is a mainstay of migraine treatment due to its efficacy and safety. Many migraine 
medications contribute to weight gain such as beta-blockers and antidepressants, and migraine 
itself may predispose to weight gain and metabolic syndrome.  [46] The potential of topiramate 
to reduce weight may desirable. The other potential benefits of topiramate include less need for 
acute treatment especially those who overuse medications, more effective treatment with acute 
medications, lower attack severity and overall cost savings. Although migraine prevention 
remains underutilized {Lipton, Silberstein}, topiramate is among the most attractive and popular 
treatments. Topiramate is not specifically indicated for chronic migraine, unlike 
Onabotulinumtoxin A, but appears effective based on clinical trials. Advantages of topiramate 
compared to Onabotulinumtoxin A include cost and no need to perform injections on a regular 
basis; the disadvantage is increased AEs. Given the disparity in cost, many insurance providers 
will require a trial of other medication treatments such as topiramate before authorizing 
Onabotulinumtoxin A injections for migraine, even if the patient has chronic migraine. 
Topiramate’s efficacy is well-established for migraine, but long-term data and outcomes are less 
clear. An observational study performed at our center [6]suggested that in a real-world setting 
topiramate dosing varies widely between patients. Patients with chronic migraine and intracranial
hypertension were more likely to take topiramate at doses beyond 100 mg, and those with co-
existing medical problems such as bipolar disorder, obesity, epilepsy received it more often. Only
a minority of patients used topiramate for more than 1 year. Some patients discontinued due to 
lack of benefit or AEs, others due to migraine remission or plans for pregnancy. Ultimately 
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topiramate clinicians will continue to utilize topiramate for patients with frequent or disabling 
migraine until more effects treatments are found with fewer AEs.  
Drug Summary Box:
Drug Topiramate
Phase IV
Indication Migraine Prophylaxis
Pharmacology Increases activity at GABA-A receptors; inhibits carbonic 
anhydrase; blocks voltage-dependent sodium and calcium 
channels;  antagonist of the of AMPA/kainate subtype of the 
glutamate receptor 5-HT2C receptors 
Route of Administration Oral
Chemical structure 2,3:4.5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose 
sulfamate
Pivotal trials Brandes et al. JAMA 2004; Silberstein et al., Arch Neurol 2004; 
Hershey et al. Headache 2013.
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